Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![FDA Approved healthcare-GettyImages-2262063057]( "FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy")
FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy7/9/2026Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.
-
![Business man running on arrow shaped bridge-GettyImages-1686497935]( "How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale")
How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale6/29/2026Our latest Cell & Gene Live examined how CGT developers can choose manufacturing models that support long-term commercial success by aligning biology, operations, supply chain, and scalability from the earliest stages of development.
-
![26_06_C&GPod_FTE]( "In Vivo Gene Editing Is Moving From Promise To Proof")
In Vivo Gene Editing Is Moving From Promise To Proof6/15/2026CGT is shifting from technical promise to clinical execution as in vivo approaches reach an inflection point where delivery, durability, specificity, and manufacturability will determine whether the field can turn breakthrough science into safe, scalable, repeatable therapies.
-
![GettyImages-1248408993]( "Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT")
Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT6/2/2026Gene therapy’s next test is not proving it works, but proving it can scale.
-
![26_05_CGL]( "CGT Manufacturing Shifts From Capacity To Strategy")
CGT Manufacturing Shifts From Capacity To Strategy5/21/2026As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.
-
![regulations, rules, guidelines, laws, compliance and standards, compliance-GettyImages-2186729096]( "Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook")
Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook5/13/2026At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.
-
![Sense of hearing, auditory perception-GettyImages-2159129607]( "Regeneron Advances In Vivo Gene Therapy For Hearing Loss")
Regeneron Advances In Vivo Gene Therapy For Hearing Loss5/1/2026Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.
-
![Diabetes Type 1, application new technology in future medicine-GettyImages-837092948]( "Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D")
Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D4/27/2026Sana Biotechnology and Mayo Clinic are partnering to standardize delivery of a one-time hypoimmune cell therapy, aiming to scale access and redefine care for type 1 diabetes.
-
![woman scientist with protective goggle and gloves-GettyImages-918825222]( "Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry")
Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry4/17/2026Here's why trafficking and entry remain key barriers to CAR T success in solid tumors.
-
![CAR T cells-GettyImages-2243155532]( "Target Selection Drives The Future Of CAR T Therapy In Solid Tumors")
Target Selection Drives The Future Of CAR T Therapy In Solid Tumors4/13/2026Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.
